Liquidity Without Liquidation
STRATEGY • SHARE FINANCING • LIQUIDITY
The Strategic Case for Borrowing Against Shares
The central idea: a share-backed loan can turn a concentrated equity position into usable capital without an immediate sale—but the strategy succeeds only when the financing is sized for volatility, matched to a credible repayment source, and documented with eyes wide open. |
A shareholder can be wealthy on paper and still face a very practical problem: the opportunity, tax payment, acquisition, property closing, or business investment in front of them requires cash—not a brokerage statement.
The obvious answer is to sell shares. It is also the answer that can create the most collateral consequences. A sale may reduce voting power, interrupt a long-term investment thesis, create market signaling, affect control, or accelerate a taxable event depending on the holder’s circumstances and jurisdiction. For a founder, executive, family office, or major investor, the sale itself can be strategically expensive even before taxes and transaction costs enter the picture.
Borrowing against eligible publicly traded shares offers another route. The shareholder pledges securities as collateral to an independent lender and receives financing based on a fraction of their value. The shares remain the economic foundation of the transaction; cash becomes available without an immediate open-market disposal. That is liquidity without liquidation.
But this is not financial alchemy. The sale has not vanished—it has become a risk to be managed. If collateral value falls, financing costs rise, or repayment plans fail, the lender’s rights may include demanding more collateral, requiring a paydown, or liquidating pledged shares. The strategic question is therefore not simply, “Can I borrow?” It is, “Does this loan improve my total position after cost, volatility, control, tax timing, and downside risk are considered?”
Why selling can be more expensive than the price on the screen
For a small, diversified holding, selling may be clean and sensible. For a large or concentrated shareholder, the true cost can be multidimensional.
Ownership and control. Selling can dilute voting influence, reduce a strategic stake, or complicate shareholder agreements and succession plans.
Market impact. A block sale may be difficult to execute without price pressure, especially in a thinly traded security.
Signaling. Sales by founders, directors, or other visible holders can be interpreted by the market—fairly or not—as a loss of conviction.
Tax timing. A sale may recognize gains immediately. Borrowing generally is not itself sale proceeds, but tax treatment is fact-specific and must be confirmed by qualified advisors.
Opportunity cost. Selling eliminates some or all future participation in the position’s upside. Borrowing can preserve that exposure, subject to the loan structure and the very real possibility of downside.
Execution constraints. Lockups, insider-trading policies, closed trading windows, reporting duties, local law, and contractual restrictions may limit what a shareholder can pledge or sell.
A loan can be valuable because it separates two decisions that are often forced together: the decision to obtain cash today and the decision to exit an equity position. That separation creates options. Options, however, have a price—the interest expense and the risk attached to collateral.
How share-backed financing works
At a high level, the mechanics are straightforward:
Eligibility review. A prospective lender assesses the issuer, exchange, jurisdiction, market capitalization, free float, trading volume, volatility, ownership concentration, transferability, and any legal or contractual restrictions.
Valuation and advance rate. The lender assigns a lendable value to eligible shares. A lower-volatility, liquid security may support a higher advance rate than a concentrated, volatile, or thinly traded position.
Documentation and collateral control. The borrower and lender execute loan and collateral documents. Custody, control, voting, dividends, corporate actions, hedging permissions, and sale rights must be understood—not assumed.
Funding. The lender advances cash, commonly at a floating benchmark plus a spread or under another agreed pricing structure. Fees and minimum interest periods may also apply.
Monitoring. Collateral coverage is monitored during the term. A decline in share price—or a lender change to eligibility or required collateral—can reduce borrowing capacity.
Repayment or enforcement. The borrower repays from a planned source. If contractual requirements are not met, lender remedies can include additional-collateral demands, partial paydown, or sale of pledged securities.
The little equation that runs the whole strategy
Loan-to-value (LTV) is the loan balance divided by the current collateral value:
LTV = Loan balance ÷ Market value of pledged shares
Suppose eligible shares are worth $20 million and a borrower draws $6 million. Initial LTV is 30%. If the share price falls 40%, the collateral becomes worth $12 million and LTV rises to 50%—even though the borrower has not drawn another dollar. Interest added to the balance can push it higher still.
The practical lesson: maximum borrowing capacity is not the same as prudent borrowing capacity. A cushion is not idle space; it is risk budget. |
When borrowing can be strategically compelling
1. A defined bridge with a visible exit
The cleanest use is often temporary: bridge a property closing until another asset is sold, fund working capital until a receivable or distribution arrives, or meet a near-term obligation before a known liquidity event. The clearer and less market-dependent the repayment source, the stronger the structure.
2. Preserving a high-conviction or control position
A founder or long-term holder may have reasons—economic, governance-related, or personal—to avoid reducing a stake. Financing may preserve ownership and future appreciation potential. The catch is that conviction is not collateral protection. A stock can be an excellent long-term investment and still experience a drawdown large enough to stress a loan today.
3. Funding a higher-value use of capital
Liquidity may support an acquisition, business expansion, real estate transaction, or diversification program. The correct comparison is not simply expected investment return versus the loan’s headline rate. It is the risk-adjusted value of the funded use versus the all-in financing cost, including fees, taxes, hedging, currency effects, and the possibility of forced action during a market decline.
4. Managing the timing of a sale
Borrowing may defer an immediate disposition while the shareholder coordinates tax advice, trading windows, corporate approvals, estate planning, or an orderly sale program. “Defer” is the operative word. A future sale may still be the repayment source, and neither tax benefits nor future prices are guaranteed.
5. Creating balance-sheet flexibility
For a family office or entrepreneur, a committed financing facility can provide optionality when opportunities arrive faster than traditional financing. Even here, unused availability should not become an invitation to over-borrow. Flexibility is most valuable when paired with rules for when—and when not—to draw.
The risks deserve equal billing
Securities-backed borrowing can be efficient, but the collateral is marked by markets that do not care about anyone’s repayment calendar.
Collateral-call and liquidation risk. If pledged value falls below contractual requirements, the borrower may have to add cash or securities, repay part of the loan, or face a lender-directed sale. The response window may be short, and the borrower may not control which assets are sold.
Concentration and volatility risk. A single-company position can gap down on earnings, litigation, regulation, management news, or sector shocks. Historical volatility is informative, not a ceiling.
Interest-rate and negative-carry risk. Many facilities use a floating benchmark plus a spread. If rates rise while collateral value falls, cost and coverage can deteriorate together. The shares are not guaranteed to appreciate faster than interest accrues.
Term and renewal risk. A facility may mature, become repayable on demand, or be subject to eligibility changes. A plan that relies on indefinite renewal is not an exit plan.
Documentation risk. Recourse, title transfer, rehypothecation, custody, voting, dividends, corporate actions, hedging, cure periods, events of default, and governing law can materially change the economics.
Counterparty and fraud risk. Borrowers should verify the lender, custody chain, regulatory standing where applicable, and destination of pledged assets. Upfront-fee pressure, vague documentation, guaranteed approvals, or promises of risk-free funding deserve scrutiny.
Tax, legal, and regulatory risk. Treatment varies by jurisdiction and facts. A pledge, transfer, enforcement sale, dividend arrangement, insider status, or cross-border structure can have consequences beyond the loan itself.
Currency risk. If the loan currency differs from the borrower’s income, repayment source, or collateral currency, exchange-rate moves can add an independent layer of leverage.
A disciplined decision framework
A robust analysis starts with downside cases, not the requested proceeds.
Define the exact use, amount, timing, and economic benefit of the cash.
Identify at least one primary and one backup repayment source that do not depend on the pledged shares rising.
Stress-test collateral at meaningful drawdowns—such as 20%, 40%, and 60%—and include accrued interest, fees, currency moves, and changes in advance rates.
Size the initial LTV so the facility can absorb volatility without forcing action at the worst moment.
Map every trigger: maintenance threshold, cure period, lender discretion, concentration limit, maturity, and event of default.
Confirm who holds the shares, whether title transfers, whether assets may be rehypothecated, and what happens to voting rights, dividends, and corporate actions.
Compare against alternatives: partial sale, staged sale, traditional bank credit, real-estate financing, private credit, hedging, or simply delaying the expenditure.
Have independent legal, tax, investment, and accounting advisors review the structure in every relevant jurisdiction.
Stress test: what happens to LTV?
Share-price move | Collateral value | Loan balance* | Resulting LTV |
0% | $20.0m | $6.0m | 30% |
–20% | $16.0m | $6.0m | 37.5% |
–40% | $12.0m | $6.0m | 50% |
–60% | $8.0m | $6.0m | 75% |
*Illustrative only; excludes interest, fees, changing collateral haircuts, and other adjustments. It is not a loan offer or prediction.
Questions sophisticated borrowers ask before signing
What entity is the actual lender, and who regulates it in the relevant jurisdiction?
Is the facility recourse or non-recourse, and what precisely limits recourse?
What is the initial advance rate, maintenance threshold, and liquidation threshold?
Can anything be changed at the lender’s discretion?
How quickly must a collateral call be cured? Is notice required?
Who is custodian? Does legal title transfer? May shares be lent, sold, hedged, or rehypothecated?
Who receives dividends, votes proxies, and controls corporate-action elections?
What benchmark, spread, default rate, fees, minimum interest, and prepayment terms apply?
What restrictions apply to insiders, control persons, pledged shares, legends, lockups, or reporting obligations?
What happens on a trading halt, delisting, merger, tender offer, rights issue, or extraordinary dividend?
What is the repayment plan if the shares fall 50% and refinancing is unavailable?
What “good” looks like
A strong share-financing transaction tends to have a modest initial LTV, liquid and eligible collateral, transparent custody, clearly defined lender rights, a term matched to the use of funds, and a repayment source outside the collateral itself. It also survives an uncomfortable stress test.
A weak transaction often begins at maximum leverage, depends on appreciation to repay, hides important economics in fees or discretionary clauses, or asks the borrower to trust a process they cannot independently verify. The difference is less about a seductive rate and more about resilience.
Borrowing against shares is not a substitute for selling. It is a tool for controlling when, how, and under what conditions a sale might occur. Used well, it creates time and choice. Used carelessly, it can surrender both. |
The Altivolus role
Altivolus Capital Partners, through Altivolus Stock Loans, helps qualifying founders, executives, family offices, international business owners, and significant shareholders explore potential securities-backed financing opportunities. Altivolus acts solely as an introducer and finder, connecting prospective borrowers with independent third-party financing providers. Altivolus is not the lender and does not make underwriting decisions, structure or negotiate loans, or provide investment, legal, or tax advice. Loan availability and terms are determined solely by the lender and vary by security, jurisdiction, borrower, and market conditions.
If the strategic objective is liquidity without an immediate sale, the next step is not to chase the highest advance rate. It is to establish eligibility, clarify the use and exit, and compare credible structures with the downside fully visible.
Explore share-financing possibilities at AltivolusStockLoans.com
Comments